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AS1069562 is the (þ)-isomer of indeloxazine, which had been clinically used as a cerebral activator for
the treatment of cerebrovascular diseases with serotonin and norepinephrine reuptake inhibition (SNRI)
and neuroprotection. Here, we compared the analgesic effects of repeated treatment with AS1069562
and duloxetine, a selective SNRI, on pain-related behavior in a rat model of streptozotocin (STZ)-induced
diabetic neuropathy. Further, we also evaluated the effects on the expression of neurotrophic factors and
nerve conduction velocity. AS1069562 and duloxetine by single daily administration for 4 weeks
signiﬁcantly improved mechanical allodynia in STZ-induced diabetic rats and did not affect plasma
glucose level or body weight. Interestingly, the analgesic effect of AS1069562 continued after a
consecutive 1-week treatment discontinuation, although the plasma concentration of AS1069562 was
reduced to undetectable levels. In contrast, the efﬁcacy of duloxetine disappeared after treatment
discontinuation. Expression analysis demonstrated that AS1069562 signiﬁcantly restored decreased
insulin-like growth factor 1 and ﬁbroblast growth factor 2 mRNA levels in dorsal root ganglion and spinal
cord, respectively, whereas duloxetine did not affect the expression levels of neurotrophic factors. In
addition, AS1069562 reversed the slowing of nerve conduction velocity. The results of this study indicate
that the analgesic effect of repeated dosing of AS1069562 but not duloxetine is persistent even after a
1-week drug discontinuation in STZ-induced diabetic rats. Restoration of neurotrophic factors may be
involved in the curative-like pharmacological effect of this agent. Thus, AS1069562 may potentially offer
a better treatment option for patients with painful diabetic neuropathy than duloxetine via different
mechanisms.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Diabetic neuropathy is one of the most common complications
of diabetes mellitus. Patients with this neuropathy experience
symptoms such as spontaneous pain, allodynia, and hyperalgesia
with an incidence rate of 10e20% (Dyck et al., 1993; Harati, 1996).
Symptoms of painful diabetic neuropathy are highly unpleasant for
affected individuals and usually disruptive to daily life.: þ81 29 856 2515.
Murai).
r Ltd.Open access under CC BY-NC-NDSerotonin (5-HT) and norepinephrine (NE) are implicated in the
modulation of endogenous analgesic mechanisms via the
descending inhibitory pain pathways in the central nervous system.
5-HT and NE reuptake inhibitors (SNRIs) are thought to exert an
analgesic effect by enhancing the serotonergic and noradrenergic
descending inhibition system. Antidepressants such as duloxetine,
an SNRI, are often used for the treatment of neuropathic pain in
patients with painful diabetic neuropathy. Although the clinical
effects of SNRIs have been well established, their beneﬁcial effects
are based on transient symptomatic relief of pain, and they cannot
cure the underlying condition itself. Thus, there are critical unmet
needs for new drugs which exert a long-term analgesic effect on
painful diabetic neuropathy.
Indeloxazine is an SNRI with potential antidepressant proper-
ties. This drug had been used for the treatment of psychiatric license.
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stroke depression, emotional disturbance, and reduced volition,
in Japan and South Korea (Yamamoto, 1990). In experimental ro-
dent studies, indeloxazine has shown multiple pharmacological
actions, including 5-HT and NE reuptake inhibition, facilitation of
acetylcholine release in the frontal cortex, and neuroprotective
effects after ischemic brain injury (Yamaguchi et al., 1997).
AS1069562 is the optical (þ)-isomer separated from a racemic
compound, indeloxazine. Compared to indeloxazine, AS1069562
was approximately 25 times less potent in inhibiting NE uptake and
about 3 times less potent in central arousal activity in rodents. On
the other hand, AS1069562 was equipotent to indeloxazine in
inhibiting 5-HT uptake and in affecting learning behavior in ro-
dents (Shimizu-sasamata et al., 1993).
Streptozotocin (STZ), which selectively destroys pancreatic
b cells (Rakieten et al., 1963), rapidly induces diabetes in rodents in
a model of insulin-dependent diabetes mellitus. Prolonged hyper-
glycemia, hypoinsulinemia, and abnormal glucose metabolism
cause the degeneration of neurons (Courteix et al., 1993). Decreases
in neurotrophic factors occur in STZ-induced diabetic animals, as in
patients with diabetic neuropathy, and this in turn exacerbates the
degeneration of neurons (Craner et al., 2002; Guo et al., 1999).
Slowing of nerve conduction velocity, a conventional electrophys-
iological parameter that reﬂects the severity of nerve dysfunction,
also occurs in STZ-induced diabetic animals as in patients with
diabetic neuropathy (Calcutt et al., 1996; Sharma and Thomas,
1974). In addition, STZ-induced diabetic rats show neuropathic
pain, characterized bymechanical and thermal allodynia, one of the
symptoms of diabetic neuropathy (Calcutt et al., 1996). Gabapentin,
pregabalin, amitriptyline, mexiletine, and morphine, but not
diclofenac, inhibit allodynia in a rodent model of STZ-induced
diabetic neuropathy (Courteix et al., 1994; Field et al., 1999;
Kiguchi et al., 2004; Ulugol et al., 2002; Yamamoto et al., 2009),
suggesting that the STZ model is suitable for evaluating the clinical
potential of compounds for treating painful diabetic neuropathy.
Here, we compared the analgesic effects of repeated treatment
with AS1069562 and duloxetine on pain-related behavior in a rat
model of diabetic neuropathy. Results showed that AS1069562 has
a curative-like analgesic effect. The effects of AS1069562 and
duloxetine on expression levels of neurotrophic factors in the
dorsal root ganglion (DRG) and spinal cord as well as on nerve
conduction velocity in the sciatic nerve were investigated after
treatment discontinuation.
2. Materials and methods
2.1. Animals
Male SpragueeDawley (SD) rats (Charles River Laboratories Japan; Yokohama,
Japan) were housed in polycarbonate cages with clean paper chips as bedding under
controlled lighting (12-h light/dark cycle, lights on at 7:30 a.m.) and temperature
(23  1 C). Rats had free access to water and food throughout the experiment. All
animal experimental procedures were approved by the Animal Experiment Com-
mittee of Astellas Pharma Inc. All efforts were made to minimize the number of
animals used and their suffering.
2.2. Induction of diabetes
Diabetic mellitus was induced via a single intravenous injection of STZ (Sigma,
St. Louis, MO, USA) dissolved in pH 4.5 citrate buffer into the tail vein at a dose of
45 mg/kg. Age-matched control animals were injected with vehicle only. Animals
were fasted from the evening prior to the day of STZ administration and were
allowed to feed again after administration. Two weeks after STZ injection, plasma
glucose levels were measured to examine the development of hyperglycemia, and
rats with plasma glucose levels below 300 mg/dl were excluded from the study.
2.3. Measurement of plasma glucose levels
Blood samples were collected via the tail vein at 2 and 7 weeks after STZ in-
jection. Plasma glucose levels were measured using the mutarotase-GOD method
(Glucose C2; Wako Pure Chemical Industries, Osaka, Japan).2.4. Drug administration
(R)-2-[(1H-inden-7-yloxy)methyl]morpholinemonobenzenesulfonate (AS1069562)
and duloxetine were synthesized at Astellas Pharma Inc. (Tokyo, Japan). Hydrochloride
salts of AS1069562 andduloxetinewereused asAS1069562 andduloxetine, respectively.
For in vivo studies, AS1069562 and duloxetine were suspended in distilled water and
administered orally at avolumeof 5ml/kg. Drug concentrationswere calculated in terms
of the free base. AS1069562 and duloxetine were administered at doses of 3, 10, and
30 mg/kg. At the doses AS1069562 and duloxetine enhanced 5-HT and NE transmission
resulting fromblockadeof 5-HTandNE reuptake sites in rodent brain (Shimizu-sasamata
et al., 1993; Koch et al., 2003). Administrations of AS1069562 and duloxetine were initi-
ated at 3weeks after STZ injection, and treatmentwasmaintained daily for 4weeks. The
measurement of mechanical allodynia was performed at 1 and 3 h after ﬁrst and last
dosing of AS1069562 and duloxetine, respectively, representing time points with
approximately maximum plasma concentration levels of the tested agents.
2.5. Pharmacokinetic study
Plasma samples were collected at 1 h after AS1069562 administration of
30 mg/kg in STZ-treated rats. At the same time points as used in mechanical
allodynia measurements, plasma samples were collected after 4-week chronic
administration of AS1069562 at 30 mg/kg and a consecutive 1-week treatment
discontinuation. Three rats were used in each group. Samples were stored at
20 C until use. Plasma samples were treated by protein precipitation with
acetonitrile. After centrifugation (1500 g, 10 min, 4 C), the supernatant was
separated and used for analysis. The concentration of AS1069562 in the samples
was quantiﬁed using high-performance liquid chromatography (Shimadzu Corp.,
Kyoto, Japan) coupled with a triple quadrupole mass spectrometer (API4000,
Applied Biosystems, Rockville, MD, USA).
2.6. Measurement of mechanical allodynia (von Frey test)
Measurements of mechanical allodynia in STZ-injected rats were performed as
described previously (Yamamoto et al., 2009). Rats were placed in acrylic cages with
awire grid ﬂoor and allowed to sit in a quiet room for 20e40min prior to the start of
tests. Before paw stimulation, the animals were quiet, but not lying on their paws,
and had ceased to explore their cages or tomark them by defecating or urinating. An
electronic von Frey system, which consists of a hand-held force transducer ﬁtted
with a 0.7 mm2 polypropylene tip (electronic von Frey anesthesiometer, IITC Life
Science Inc., Woodland Hills, CA, USA) was used. The tip was placed perpendicularly
against the plantar surface of the hind paw with gradually increasing pressure.
Actions such as vocalization, agitation, jumping, and avoidance were considered to
be indicative of a withdrawal threshold. Voluntary movement associated with
locomotion was not considered to be a withdrawal response. The force required to
elicit a withdrawal response was recorded twice for each hind paw with an interval
of at least 3 min. The mean of the four values was considered the withdrawal
threshold (g) for each rat. Three weeks after STZ injection, the withdrawal threshold
was measured for each rat, and rats were randomly assigned to experimental groups
(control, vehicle-treated STZ, and AS1069562 or duloxetine at 3, 10, or 30 mg/kg-
treated STZ) in such a way as to minimize the differences among group averages.
Analgesic studies were performed after a single and 4-week chronic administration
of drugs and after 1-week treatment discontinuation. Thirteen or fourteen rats were
used in each group. All behavioral responses were measured by a researcher who
was blinded to treatment group.
2.7. Gene expression analysis
Changes in gene expression were analyzed by quantitative polymerase chain
reaction (PCR) analysis using the ABI PRISM 7900 sequence detection system
(Applied Biosystems, Foster City, CA, USA)with SYBRGreen PCRMasterMix (Applied
Biosystems) according to the manufacturer’s instructions. Brieﬂy, DRGs and spinal
cord from the L4-L6 region were isolated from control, vehicle-treated STZ,
AS1069562-treated STZ, and duloxetine-treated STZ rats after 1-week treatment
discontinuation of drugs at 30 mg/kg. Samples were obtained from three to six rats
in each group, and total RNAwas prepared with Trizol reagent (Invitrogen, Carlsbad,
CA, USA) and an RNeasy kit (Qiagen N.V., Venlo, the Netherlands) according to the
manufacturer’s instructions. Puriﬁed total RNA was reverse-transcribed to com-
plementary DNA (cDNA) using Superscript III reverse transcriptase (Invitrogen) with
random primers (Invitrogen). The cDNA was subjected to quantitative PCR analysis.
Primers used to detect themessenger RNA (mRNA) for each gene are listed in Table 1.
Gene expression was normalized to the expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH).
2.8. Measurement of motor nerve conduction velocity (MNCV)
MNCVwasmeasuredwith a Synax 1200 (NECMedical Systems, Tokyo, Japan) by
modiﬁcation of a previously reported method (Cameron et al., 1989). Rats were
anesthetized with pentobarbital, and rectal temperature was maintained at
37  1 C with a heating blanket. The sciatic nerve was exposed and electrophysi-
ological recordings were carried out by placing the recording electrode around the
gastrocnemius muscle of the foot and the stimulating electrode close to the sciatic
Table 1
Oligonucleotide primers used for quantitative PCR analysis of gene expression. Abbreviations: FGF1, ﬁbroblast growth factor 1; FGF2, ﬁbroblast growth factor 2; IGF1, insulin-
like growth factor 1; NGFb, nerve growth factor b; BDNF, brain-derived neurotrophic factor; S100b, S100 calcium binding protein B; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
Gene Gene symbol RefSeqID Forward primer Reverse primer
FGF1 Fgf1 NM_012846 50-TGTTCCCTTGACCATTGGCT-30 50-AATTCAGGCTCTGTGGGCTG-30
FGF2 Fgf2 NM_019305 50-GAGAAGAGCGACCCACACGT-30 50-TCCTCTCTCTTCTGCTTGGAGC-30
IGF1 Igf1 NM_178866 50-GCTGGTGGACGCTCTTCAGT-30 50-TTGAAGTAAAAGCCCCTTGGTC-30
NGFb Ngf XM_227525 50-GATCGGCGTACAGGCAGAAC-30 50-TCTCCCTCTGGGACATTGCT-30
BDNF Bdnf NM_012513 50-AGGCACTGGAACTCGCAATG-30 50-AAGGGCCCGAACATACGATT-30
S100b S100b NM_013191 50-AGTGATGGAGACGCTGGACG-30 50-TCCTGGAAGTCACACTCCCC-30
GAPDH Gapdh NM_017008 50-CTTCTTGTGCAGTGCCAGCC-30 50-CACCGACCTTCACCATCTTGT-30
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was delivered with supramaximal current, and 10 consecutive traces were recorded.
MNCV was calculated by dividing the distance between the two stimulating elec-
trodes by the averaged latency differences between the onset of M-waves evoked
from the two sites. MNCV was evaluated in control, vehicle-treated STZ, and
AS1069562 at 30 mg/kg-treated STZ rats after 1-week discontinuation of treatment.
Ten or twelve rats were used in each group.
2.9. Experimental protocol
To evaluate the clinical potential of drugs for treating painful diabetic neurop-
athy, STZ-induced diabetic rats were prepared by STZ injection. Twoweeks after STZ
injection, plasma glucose levels were measured to examine the development of
hyperglycemia. Three weeks after STZ injection, administrations of drugs were
initiated, and treatment was maintained daily for 4 weeks to evaluate the effects of
single and repeated treatment of drugs. After a single administration of drugs,
mechanical allodynia was measured. After 4-week chronic administration of drugs,
plasma glucose levels, body weights andmechanical allodynia were measured. After
1-week treatment discontinuation, measurements of mechanical allodynia, gene
expression analysis, and measurement of MNCV were performed.
2.10. Statistical analysis
Data were expressed as the mean  S.E.M. Signiﬁcance of differences between
two groups was assessed using Student’s t test, while differences among more than
two groups were assessed using Dunnett’s multiple comparison test. p < 0.05 was
considered signiﬁcant.
3. Results
3.1. Effects of single and chronic administration of AS1069562 and
duloxetine on mechanical allodynia in STZ-induced diabetic rats
Diabetic neuropathy was induced by administration of STZ in
rats. STZ at 45 mg/kg signiﬁcantly decreased the withdrawal
threshold in response to stimuli to the hind paw with an electric
von Frey system from 3 to 7 weeks after injection, indicating the
animals had persistent mechanical allodynia, a symptom of
neuropathic pain in STZ-induced diabetic neuropathy. Single daily
oral administration of AS1069562 and duloxetine for 4 weeks wasFig. 1. Analgesic effects of AS1069562 (A) and duloxetine (B) after single oral administration
and duloxetine were orally administered 1 h and 3 h, respectively, before the von Frey test. D
test compared with the control group. **, p < 0.01 by Dunnett’s test compared with the veinitiated at 3 weeks after STZ injection. Both AS1069562 and
duloxetine induced signiﬁcant recovery in withdrawal threshold
after the ﬁrst dosing at 30 mg/kg (Fig. 1A and B) and after the last
dosing at over 10 mg/kg (Fig. 2A and B). Furthermore, the von Frey
test was also performed after a 1-week drug washout to investigate
the persistence of the analgesic effects of these agents. Interest-
ingly, the analgesic effect of AS1069562 continued after consecutive
1-week treatment discontinuation, whereas that of duloxetine
completely disappeared. Signiﬁcant recovery of withdrawal
threshold was maintained at over 10 mg/kg of AS1069562 (Fig. 3A
and B). These results demonstrated that AS1069562 has a longer-
lasting analgesic effect than duloxetine when administered for
4 weeks in a rat model of STZ-induced diabetic neuropathic pain.
3.2. Effects of chronic administration of AS1069562 and duloxetine
on plasma glucose level and body weight in STZ-induced diabetic
rats
To exclude the possibility that the analgesic effects described
above might be confounded by hypoglycemic effects and global
amelioration in diabetic condition caused by the drugs, we exam-
ined their effects on plasma glucose level and body weight after
4-week chronic administration. Results showed no signiﬁcant dif-
ferences between the vehicle-treated and AS1069562- or
duloxetine-treated groups in plasma glucose level (Fig. 4) or body
weight (Fig. 5).
3.3. Effects of chronic administration of AS1069562 on plasma
concentration of AS1069562 in STZ-induced diabetic rats
Measurements of plasma concentrations of AS1069562 were
performed 1 day as well as 4 weeks after the start of drug admin-
istration and also after the consecutive 1-week washout in
STZ-induced diabetic rats. Plasma concentrations of AS1069562 aton mechanical allodynia in a rat model of STZ-induced diabetic neuropathy. AS1069562
ata are presented as the mean  S.E.M. for 13 or 14 rats. ###, p < 0.001 by Student’s t
hicle-treated group.
Fig. 2. Analgesic effects of AS1069562 (A) and duloxetine (B) after single daily oral chronic administration for 4 weeks on mechanical allodynia in a rat model of STZ-induced
diabetic neuropathy. AS1069562 and duloxetine were orally administered 1 h and 3 h, respectively, before the von Frey test. Data are presented as the mean  S.E.M. for 13 or
14 rats. ###, p < 0.001 by Student’s t test compared with the control group. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 by Dunnett’s test compared with the vehicle-treated group.
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were 204 and 177 ng/ml, respectively, in STZ-treated rats. There
was no signiﬁcant difference in plasma concentration between
single and 4-week administration. Plasma levels of AS1069562
were not detectable after the consecutive 1-week washout. The
prolonged analgesic effect of AS1069562 observed after the 1-week
drug washout was therefore not dependent on the continued
presence of the drug in the plasma.
3.4. Effects of chronic administration of AS1069562 and duloxetine
on expression levels of neurotrophic factors in STZ-induced diabetic
rats
To determine the effects of AS1069562 and duloxetine on
expression levels of neurotrophic factors in DRG and spinal cord,
we performed quantitative PCR analysis of tissue samples from rats
subjected to 4-week administration of AS1069562 and duloxetine
at 30 mg/kg and a consecutive 1-week drug washout period. In
order to investigate the different mechanism of AS1069562 from
that of duloxetine to exert a curative-like analgesic effect, we
selected the dose of 30 mg/kg, at which dose AS1069562 and
duloxetine exerted different effects. DRG and spinal cord samples
were collected from the L4, L5, and L6 levels because these levels
receive input from the hind paw footpad, in which mechanical
allodynia was measured. The results of quantitative PCR analysis
are shown in Table 2. In L4, L5, and L6 DRGs from vehicle-treated
STZ-induced diabetic rats, mRNA levels of ﬁbroblast growth factor
1 and 2 (FGF1 and FGF2), insulin-like growth factor 1 (IGF1), and
brain-derived neurotrophic factor (BDNF) were signiﬁcantly
reduced compared with normal control rats. In spinal cord from theFig. 3. Analgesic effects of AS1069562 (A) and duloxetine (B) after a 1-week treatment disco
Data are presented as the mean  S.E.M. for 13 or 14 rats. ###, p < 0.001 by Student’s t
compared with the vehicle-treated group.L4-L6 region, mRNA level of FGF2 was signiﬁcantly reduced
compared with normal control rats. The expression of IGF1 in the
DRGs and of FGF2 in the spinal cord was signiﬁcantly restored by
oral administration of AS1069562 at 30 mg/kg. It is notable that the
level of FGF2 in spinal cord was completely recovered to the control
level. In contrast, oral administration of duloxetine at 30 mg/kg did
not affect the expression levels of neurotrophic factors in DRG or
spinal cord.
3.5. Effects of chronic administration of AS1069562 on MNCV in
STZ-induced diabetic rats
To investigate the effects of AS1069562 on nerve function, we
measured MNCV of rats subjected to 4-week administration of
AS1069562 at 30 mg/kg and a 1-week treatment discontinuation.
We selected the dose of 30 mg/kg, at which dose AS1069562
showed signiﬁcant analgesic effect after consecutive 1-week
treatment discontinuation, in order to investigate the involve-
ment of nerve function in a curative-like analgesic effect of
AS1069562. MNCV of STZ-treated rats was signiﬁcantly slowed as
compared with control rats. Single daily chronic administration of
AS1069562 at 30 mg/kg for four weeks induced a partial, but sig-
niﬁcant, reversal in themotor nerve conduction impairment in STZ-
treated rats (Fig. 6).
4. Discussion
Treatment of painful diabetic neuropathy represents a major
unmet medical need. Although a variety of pain management
techniques are available, current treatments merely providentinuation on mechanical allodynia in a rat model of STZ-induced diabetic neuropathy.
test compared with the control group. *, p < 0.05; and **, p < 0.01 by Dunnett’s test
Fig. 4. Plasma glucose levels after single daily oral chronic administration of AS1069562 (A) and duloxetine (B) for 4 weeks in a rat model of STZ-induced diabetic neuropathy.
AS1069562 and duloxetine were orally administered 1 h and 3 h, respectively, before sampling blood. Data are presented as the mean  S.E.M. for 13 or 14 rats. ###, p < 0.001 by
Student’s t test compared with the control group.
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causes. Developing a drug that provides not only a symptomatic
relief from pain but also a curative-like analgesic effect would meet
the signiﬁcant unmetmedical needs of painful diabetic neuropathy.
The present study demonstrated the analgesic effects of single
and chronic administration of AS1069562 in a rat model of STZ-
induced diabetic neuropathy. In this model, single administration
of AS1069562 improved mechanical allodynia, indicating that
AS1069562 has an acute analgesic effect. Further, chronic admin-
istration of AS1069562 ameliorated mechanical allodynia. It is
notable that pain improvement was observed up to one week after
treatment discontinuation, at a time when plasma levels of
AS1069562 were no longer detectable. Together, these ﬁndings
suggest that AS1069562 provides not only symptomatic relief of
pain but also a curative-like analgesia. We also demonstrated that
single and chronic administration of duloxetine, which is used as a
standard analgesic agent for the treatment of painful diabetic
neuropathy, showed signiﬁcant anti-allodynic effects in our STZ
model, in accordance with other studies (Kuhad et al., 2009;
Mixcoatl-Zecuatl and Jolivalt, 2011), conﬁrming the predictive
validity of this diabetic neuropathy model. However, duloxetine did
not produce a long-lasting efﬁcacy following treatment discontin-
uation, indicating that duloxetine lacks a curative-like effect and
suggesting that AS1069562 might act via mechanisms different
from duloxetine. Importantly, AS1069562 and duloxetine treat-
ment did not affect hyperglycemic condition or body weight in
diabetic animals, showing that the effects of AS1069562 and
duloxetine treatment on nociceptive thresholds in diabetic rats
were not due to any normalizing effects on hyperglycemia and
body weight loss, which are indexes of global amelioration of dia-
betic condition.Fig. 5. Body weight after single daily oral chronic administration of AS1069562 (A) and du
presented as the mean  S.E.M. for 13 or 14 rats. ###, p < 0.001 by Student’s t test compaIt has been documented that one possible mechanism of the
deterioration of sensory neurons in painful diabetic neuropathy is
the loss of neurotrophic support. Neurotrophic factors are proteins
that promote the development, survival and maintenance of spe-
ciﬁc neuronal populations. They cause responsive neuronal pop-
ulations to be more resistant to injury, enhance their physiologic
activity, and might also stimulate regeneration (Leinninger et al.,
2004). Several neurotrophic factors have been tested in animal
models of diabetic neuropathy with variable success (Apfel, 2002;
Calcutt et al., 2008). To clarify the mechanisms mediating the
curative-like effect of AS1069562 in STZ-induced diabetic neurop-
athy, we investigated the expression levels of neurotrophic factors
in DRG and spinal cord. Results showed that the expression level of
IGF1 in DRGs of STZ-induced diabetic rats was signiﬁcantly
reduced, in accordance with a previous study (Craner et al., 2002),
and signiﬁcantly restored by chronic administration of AS1069562.
In addition, the expression level of FGF2 in spinal cord of STZ-
treated rats was signiﬁcantly reduced and restored to the normal
level by chronic administration of AS1069562. Several studies have
implicated reduced levels of IGF1 and FGF2 in diabetic neuropathy.
For example, intrathecal delivery of IGF-1 improved slowing of
nerve conduction velocity, atrophy in myelinated axons, and loss of
epidermal ﬁber density and length independently of hyperglycemia
in STZ-induced diabetic rats (Brussee et al., 2004; Toth et al., 2006).
In addition, subcutaneous infusion of IGF1 prevented progressive
hyperalgesia and partially reversed impaired sensory nerve
regeneration independently of hyperglycemia in STZ-induced dia-
betic rats (Morgado et al., 2011; Zhuang et al., 1996). Further sup-
porting a role for IGF1 in diabetic neuropathy, the decrease in
circulating levels of IGF1 in patients with diabetes is greater in
those with neuropathy than in those without neuropathicloxetine (B) for 4 weeks in a rat model of STZ-induced diabetic neuropathy. Data are
red with the control group.
Table 2
RelativemRNA expression levels of neurotrophic factors in DRG and spinal cord from
the L4-L6 level of STZ-induced diabetic rats after a 1-week treatment discontinua-
tion of AS1069562 at 30 mg/kg p.o. or duloxetine at 30 mg/kg p.o. Values are
normalized to the intensity of GAPDH and expressed as the mean  S.E.M. of the
percentage of the control level for 3 to 6 rats. #, p < 0.05; ##, p < 0.01; and ###,
p < 0.001 by Student’s t test compared with the control group.*, p < 0.05; and***,
p < 0.001 by Student’s t test compared with the vehicle-treated group.
Gene Tissue Control STZ vehicle STZ AS1069562
30 mg/kg, p.o.
STZ duloxetine
30 mg/kg, p.o.
FGF1 DRG 100  9.3 65  3.3## 76  7.2 64  8.0
Spinal cord 100  8.0 85  2.8 78  6.4 83  8.1
FGF2 DRG 100  4.8 23  7.8### 21  3.5 25  4.5
Spinal cord 100  15 58  4.4# 104  4.9*** 58  6.1
IGF1 DRG 100  14 55  2.9# 68  3.2* 45  12
Spinal cord 100  8.0 67  4.8 67  2.7 67  25
NGFb DRG 100  29 107  24 151  41 100  6.9
Spinal cord 100  13 110  19 136  18 119  12
BDNF DRG 100  15 58  2.6# 64  3.0 49  7.0
Spinal cord 100  6.9 82  8.1 68  7.0 80  10
S100b DRG 100  20 55  4.6 54  6.3 50  13
Spinal cord 100  7.0 98  8.1 87  5.2 92  15
N. Murai et al. / Neuropharmacology 79 (2014) 10e16 15complaints (Guo et al., 1999; Migdalis et al., 1995). IGF1 exhibits
glycemia-independent neuroprotective effects, preventing periph-
eral nerve damage and promoting nerve regeneration, which may
account for the analgesic ability of IGF1 during painful diabetic
neuropathy. In contrast, FGF2 administered intravenously or
intramuscularly with cross-linked gelatin hydrogel improved
delayed MNCV, hypoalgesia, and sciatic nerve blood ﬂow in STZ-
induced diabetic rats (Nakae et al., 2006). Furthermore, it has
been reported that FGF2 has effects on the central nervous system
(Abe and Saito, 2001; Katsuki et al., 2000) and peripheral nervous
system (Fujimoto et al., 1997; Grothe and Nikkhah, 2001). Several
lines of evidence suggest that FGF2 improves microvascular blood
ﬂow in the endoneurial microvasculature and promotes nerve
regeneration, which might account for its ability to improve
symptomatic diabetic neuropathy. With regard to other neuro-
trophic factors, AS1069562 treatment tended to increase the level
of nerve growth factor (NGF) in DRGs in diabetic rats, although
there were no differences between control and diabetic rats. In
contrast, chronic administration of duloxetine did not affect
expression levels of neurotrophic factors in DRG or spinal cord.
Duloxetine did not exert restoration of IGF1 and FGF2 at a dose of
30 mg/kg, at which duloxetine inhibited 5-HT and NE reuptake and
increased extracellular 5-HT and NE levels, suggesting that inhibi-
tion of 5-HT and NE transporters is not involved in the effect of
AS1069562 on the two growth factors. It is well documented that
chronic treatment with SNRIs increases BDNF levels in particularFig. 6. Effects of AS1069562 after 1-week treatment discontinuation on MNCV in a rat
model of STZ-induced diabetic neuropathy. Data are presented as the mean  S.E.M.
for 10 to 12 rats. ###, p < 0.001 by Student’s t test compared with the control group. *,
p < 0.05 by Student’s t test compared with the vehicle-treated group.regions of the brain, such as the hippocampus (Calabrese et al.,
2010; Molteni et al., 2009); however, no effects on BDNF levels in
DRG or spinal cord were detectable after treatment with
AS1069562 and duloxetine. Although further investigations are
needed, the restoration of IGF1 and FGF2 expression levels suggests
that AS1069562 might improve nerve function impairment via the
amelioration of neurotrophic support.
In addition, the slowing of MNCV observed in STZ-induced dia-
betic rats (Sharma and Thomas, 1974), an endpoint used in diabetic
neuropathy patients (Arezzo et al., 2008), was signiﬁcantly
improved by chronic administration of AS1069562. Several human
and animal studies demonstrated that largemyelinated (A-b) ﬁbers
aswell as thinlymyelinated (A-d) ﬁbers and unmyelinated (C) ﬁbers
are damaged in the diabetic neuropathic conditions (Dyck et al.,
1976; Kapur, 2003). Nerve conduction velocity measurements are
commonly used to assess nerve function in diabetes and exclusively
reﬂect changes in large-diameter myelinated ﬁbers (Arezzo and
Zotova, 2002). Although the pain associated with painful diabetic
neuropathy principally reﬂects dysfunction in small-diameter or
unmyelinated (C) ﬁbers, hypersensitivity to mechanical stimulation
in diabetic rats persisted even when C ﬁber responses were abol-
ished with resiniferatoxin, a potent analog of capsaicin (Khan et al.,
2002), indicating that hypersensitivity tomechanical stimulation in
diabetic rats is mediated by myelinated (A-b and A-d) ﬁbers rather
thanC-ﬁbers. Fromthis perspective, AS1069562 in thepresent study
may likely have amelioratedmechanical allodynia and the decrease
in nerve conduction velocity mainly via its improvement of
damaged larger myelinated ﬁbers in the diabetic neuropathic con-
dition. Although the mechanism mediating the curative-like effec-
tiveness of AS1069562 is not precisely known, improvement in
nerve function via an improvement in the trophic support of neu-
rons, which include larger myelinated ﬁbers that mediate an
abnormal painful response, may well be involved.
Currently, the target molecule of AS1069562 by which it elicits
its curative-like effects remains unidentiﬁed. Previously, it was
reported that indeloxazine produces a variety of pharmacological
curative-like effects. In animal studies, indeloxazine showed anti-
hypoxic and anti-ischemic actions due in part to the enhance-
ment of energy metabolism. Indeloxazine ameliorated local cere-
bral glucose utilization in hypoxic rats (Miyaoka et al., 1988) and
protected against cerebral damage resulting from an ischemic state
in gerbils (Kano et al., 1993). Hypoxia is one of themain phenomena
in diabetes associated with several complications, and it was
demonstrated that hypoxia potentiates the activity of TRPV1, which
acts as a detector and integrator of painful stimuli in sensory
neurons (Ristoiu et al., 2011). This indicates that hypoxia might be
one cause of pain in diabetic conditions, and that anti-hypoxic ef-
fects might be involved in an analgesic effect in diabetic conditions.
In addition, indeloxazine increased the extracellular level of
acetylcholine in rat brain (Yamamoto et al., 1993). A nicotinic
acetylcholine receptor (nAChR) is involved in antinociception and
neuroprotection as well as in cognitive function. As an example of
this, the neuronal nAChR agonist ABT-594 exhibited analgesic ac-
tivity in animal models of acute, chronic, and neuropathic pain
(Kesingland et al., 2000). Furthermore, AS1069562 not only inhibits
5-HT and NE reuptake but also has an afﬁnity to 5-HT1A receptor
(data not shown), and it was reported that high-efﬁcacy 5-HT1A
receptor activation caused a curative-like action on allodynia in rats
with spinal cord injury (Colpaert et al., 2004). Although the detail
target mechanism has not been clariﬁed, in addition to the resto-
ration of expression levels of neurotrophic factors, other mecha-
nisms such as anti-hypoxia, increase of acetylcholine release, and
activation of 5-HT1A receptor might contribute to the curative-like
effect of AS1069562, which will be the future subjects to be
clariﬁed.
N. Murai et al. / Neuropharmacology 79 (2014) 10e1616In summary, this study showed that chronic dosing of
AS1069562, the (þ)-isomer of indeloxazine, but not duloxetine
caused persistent analgesia even after treatment discontinuation in
a rat model of STZ-induced diabetic neuropathy. This curative-like
analgesic effect of AS1069562 on painful diabetic neuropathy
might be mediated via the restoration of IGF1 and FGF2 expression
levels, resulting in the amelioration of nerve function impairment.
These ﬁndings suggest that AS1069562 may represent a better
treatment option for painful diabetic neuropathy than duloxetine
via different mechanisms.
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